Mr. Christopher Moreau reports

ALGERNON HEALTH AND AMERICAN MOLECULAR IMAGING ANNOUNCE STRATEGIC BUSINESS AND USD $500K INVESTMENT AGREEMENT

Algernon Health Inc. and American Molecular Imaging (AMI), one of the leading radiology reading services providers in the United States, have entered into a strategic business and investment agreement, with the goal of ensuring that all patients of Algernon's planned U.S. brain-specific neuroimaging clinics receive the highest-quality positron emission tomography (PET) scan radiology exam interpretations and reports available, within an industry-leading time frame.

Algernon's planned neuroimaging clinics will be the first dedicated, brain-optimized PET neuroimaging facilities of their kind in the United States, focused on the early-stage detection of Alzheimer's disease, and will also provide PET scans for other forms of dementia, epilepsy, neuro-oncology and movement disorders.

As part of the agreement, AMI will be awarded the exclusive radiology reading services contract for all of Algernon's planned U.S. neuroimaging clinics. AMI will also be making an aggregate $250,000 (U.S.) strategic investment in both Algernon's recently announced private placement and $250,000 (U.S.) in Algernon USA LLC, a recently created subsidiary of Algernon that will oversee all U.S. neuroimaging operations, including the opening of the first U.S.-based neuroimaging clinic, being planned for early 2026. The agreement with Algernon USA is subject to definitive documentation, which is expected to be signed within the next 60 days.

"We are very pleased to have entered into this agreement with AMI," said Christopher J. Moreau, chief executive officer of Algernon Health. "Since announcing our new Alzheimer's disease initiative, we have been carefully and methodically establishing relationships with the leading companies and experts in nuclear imaging in the U.S. By bringing together and working with the best of the best, we can ensure that we deliver the highest level of patient care possible while operating our clinics effectively and efficiently."

Dr. Jaideep Sohi, MD, chief executive officer of American Molecular Imaging, stated: "Since founding AMI, I have always strived to build a world-class company that would be recognized as a global leader in the field of nuclear medicine. We are truly excited to be a part of Algernon's plan to bring this new brain-optimized PET scan technology to the market and to join forces in making a serious contribution in the fight against Alzheimer's disease."

American Molecular Imaging is a physician-owned and -managed company that specializes in teleradiology and theranostics services. It provides specialized professional radiology interpretation, focusing on molecular imaging, nuclear medicine and diagnostic imaging exams to support health care providers nationwide.

Algernon also recently announced that it had signed a definitive equipment order, financing agreement and consulting arrangement with industry-leading Catalyst MedTech for the provision of four U.S. FDA-cleared (U.S. Food and Drug Administration) Oncovision CareMiBrain brain-specific PET scanner systems to be utilized in four planned Algernon neuroimaging medical clinics. This represents a non-dilutive deal valued at over $4-million and includes an agreement to acquire an additional six systems for the establishment of additional U.S. clinics, on an adjusted-cost basis.

Algernon will further update the market shortly on its coming expansion and growth plans, including the location of its first U.S. flagship neuroimaging clinic.

Any Algernon Health securities issued and issuable, described in this news release, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation.

About Algernon Health Inc.

Algernon Health is a Canadian health care company focused on the provision of brain-optimized PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer's disease as well as other forms of dementia, epilepsy, neuro-oncology and movement disorders. Algernon is also the parent company of a recently created private subsidiary called Algernon USA, which will oversee all U.S. neuroimaging operations.

We seek Safe Harbor.